

## Jeremy LaJoice

---

**From:** Jeremy LaJoice  
**Sent:** Tuesday, December 28, 2021 11:47 AM  
**To:** AGO - High Cost Prescription Drugs  
**Cc:** Karen Rhoades; Nimisha Bhatt  
**Subject:** RE: Vermont - New Launch of LEUPROLIDE ACETATE - Vgyaan Pharmaceuticals

Additional Details are below on the recent launch of Vgyaan's product, NDC: 72664-0611-28. The WAC on this drug is \$712.80.

- Marketing/Pricing Plan
  - Marketing Description:
    - Leuprolide Acetate Injection kit is a generic drug. We market this drug to wholesalers, mail order pharmacies, specialty pharmacies, and retail pharmacies. We do not perform paid advertising or promotions to consumers or health care providers.
  - Pricing Methodology:
    - The following is a Trade Secret. The information is known only to certain individuals within the manufacturer's organization and used in a business the organization conducts. Leuprolide Acetate Injection kit is a complex drug approved for advanced prostate cancer. Its raw materials and components are very expensive and cost several hundred thousand dollars per Kg. The finished product requires complex and high potency manufacturing equipment. In addition, this is a Kit which includes custom manufactured syringes and alcohol swabs. Lastly, the product is light and temperature sensitive. All of these considerations contribute to the high price of the product.
- The estimated volume of patients who may be prescribed the drug;
  - Estimated number of patients that may be prescribed the drug is 100,000.
- Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval; and
  - Priority review was granted by the FDA
- The date and price of acquisition if the drug was not developed by the manufacturer
  - N/A

Please let me know if you have any questions or require any additional clarification/information!

[Jeremy LaJoice](#)

EVP, Government Pricing  
Prescription Analytics, Inc.  
121 S. Wilson Ave | Hartford, WI 53027  
Office: 262.706.0439

---

**From:** Jeremy LaJoice  
**Sent:** Monday, December 13, 2021 11:46 AM  
**To:** AGO - High Cost Prescription Drugs <AGO.HighCostPrescriptionDrugs@vermont.gov>  
**Cc:** Karen Rhoades <karen@prescriptionanalytics.com>; Nimisha Bhatt <nimisha.bhatt@vgyaan.com>  
**Subject:** Vermont - New Launch of LEUPROLIDE ACETATE - Vgyaan Pharmaceuticals

Hello,

Please note that Vgyaan Pharmaceuticals has recently launched a high WAC drug, LEUPROLIDE ACETATE. We are working on compiling the data as required by state of Vermont and will work on getting that that submitted within the 30 days of launch.

Please let us know if you have any questions!

[Jeremy LaJoice](#)

EVP, Government Pricing

Prescription Analytics, Inc.

121 S. Wilson Ave | Hartford, WI 53027

Office: 262.706.0439